1st Group Enrolled in Phase 1 Trial of DA01 for Advanced Parkinson’s

1st Group Enrolled in Phase 1 Trial of DA01 for Advanced Parkinson’s

315798

1st Group Enrolled in Phase 1 Trial of DA01 for Advanced Parkinson’s

BlueRock Therapeutics’ Phase 1 trial testing DA01 — an investigational therapy to restore neuron loss — has completed enrolling its first group of patients with advanced Parkinson’s disease. Meanwhile, enrollment for the second and final high-dose cohort of the open-label trial (NTC04802733) is still ongoing at sites in the U.S. and Canada. DA01 is a treatment consisting of dopamine-producing nerve cells derived from human embryonic stem cells (ESCs). These ESCs are pluripotent, which means they…

You must be logged in to read/download the full post.